3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
12
Sarcoma
3
Neoplasm Metastasis
3
Triple Negative Breast Neoplasms
2
Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Pleural Effusion, Malignant
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Lung Neoplasms
1
Inflammatory Breast Neoplasms
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Carcinoma, Ductal, Breast
1
Carcinoma, Ductal
1
Advanced Non CNS Tumors
1
Adenocarcinoma
1
Interventions
Doxorubicin
5
pazopanib
4
Ifosfamide
3
pembrolizumab
2
Sunitinib
2
Radiotherapy, Conformal
2
Radiotherapy
2
tremelimumab
1
temsirolimus
1
sintilimab
1
saracatinib
1
sapanisertib
1
romidepsin
1
olaratumab
1
liposomal doxorubicin
1
indolepropanol phosphate
1
eribulin
1
durvalumab
1
Watchful Waiting
1
Surgical Procedures, Operative
1
Sorafenib
1
Razoxane
1
Radiotherapy, Intensity-Modulated
1
Radiation
1
Polymerase Chain Reaction
1
Observation
1
Nivolumab
1
Neoadjuvant Therapy
1
Methotrexate
1
MLN 8237
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Histiocytoma, Malignant Fibrous
×
talimogene laherparepvec
×
Clear all
No trials found.